ABMC Launches New Rapid STAT(TM) Oral Fluid Test for Drugs of Abuse

KINDERHOOK, N.Y., Oct 08, 2007 (BUSINESS WIRE) -- American Bio Medica Corporation (NASDAQ: ABMC) announced today that they have launched the patent pending Rapid STAT, a new oral fluid point of collection test. The Company has already shipped its first orders of Rapid STAT to its S&P 500 laboratory alliance, and to its European master distributor for a government tender.

The Rapid STAT oral fluid test combines the incubation benefits of the Company's OralStat(R) oral fluid device with the Company's urine based Rapid TOX(R) cassette product platform. The Rapid STAT also utilizes the same sample handling procedure of the Company's OralStat EX product launched earlier this year, thus maximizing drug recovery and providing a transport container for confirmation of positive results. The Rapid STAT provides faster test results, making it ideal for those market applications, such as roadside testing, in which portability and time is crucial. In addition to these added benefits, the Rapid STAT provides even lower THC (marijuana) testing sensitivity, making it unrivaled in the market.

ABMC Chief Executive Officer Stan Cipkowski stated, "Once again, ABMC's research and development team remains at the forefront of the drugs of abuse testing industry, providing our customers with a cost effective option in those markets where speed and versatility are essential. We've already shipped orders of this product out to customers and it is being well received. We expect the Rapid STAT to have a positive impact on sales in the rest of 2007 and going forward."

Oral fluid testing is becoming a more widely accepted alternative matrix for drugs of abuse detection. While the window of detection is more limited than traditional urine testing, oral fluid testing virtually eliminates issues associated with urine testing such as observed collection gender issues, dilution, adulteration, restroom availability, ease of specimen collection, and shy bladder.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC(R), RDS(R) InCup(R) and Rapid TOX products test for the presence or absence of drugs of abuse in urine, while OralStat and Rapid STAT tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(R) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2006, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

SOURCE: American Bio Medica Corporation

American Bio Medica Corporation
Stan Cipkowski, 800-227-1243, Ext 106
Chief Executive Officer